公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
公司地址 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
電話號碼 +1 512 501-2444
傳真號碼 +1 512 501-0414
公司網頁 https://www.cassavasciences.com
員工數量 30
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Jack Moore Senior Vice President, Clinical Development -- 21/04/2025
Mr. Richard J. Barry President, Chief Executive Officer and Director 美元 309.38K 14/04/2025
Mr. Remi Barbier Chairman of the Board, President and Chief Executive Officer 美元 1.19M 26/03/2024
Dr. Nadav Friedmann, M.D.,PhD Director and Chief Medical Officer 美元 365.00K 24/03/2022
Dr. James W. Kupiec, M.D. Chief Medical Officer 美元 449.00K 21/04/2025
Mr. R. Christopher Cook Chief Operating and Legal Officer -- 21/04/2025
Mr. Eric J. Schoen Chief Financial Officer and Principal Accounting Officer 美元 475.00K 21/04/2025
Ms. Freda Nassif Chief Business Officer -- 14/04/2025
 
董事會成員
董事會 職務 更新日期
Dr. Claude Nicaise,M.D. Chairman of the Board 14/04/2025
Mr. Richard J. Barry President, Chief Executive Officer and Director 14/04/2025
Dr. Patrick J. Scannon,M.D.,PhD Independent Director 14/04/2025
Mr. Remi Barbier Chairman of the Board, President and Chief Executive Officer 26/03/2024
Ms. Dawn Carter Bir Independent Director 22/10/2025
Dr. Nadav Friedmann, M.D.,PhD Director and Chief Medical Officer 24/03/2022
Mr. Sanford R. Robertson Lead Independent Director 26/03/2024
Mr. Pierre Gravier Independent Director 14/04/2025
Mr. Michael J. O'Donnell, Esq. Independent Director 14/04/2025
Dr. Robert Z. Gussin, PhD Independent Director 14/04/2025
Mr. Robert Anderson, Jr Independent Director 14/04/2025
 
所屬ETF (更新日期: 11/03/2026 07:30)
代號 名稱 佔比% ▼ 持有日期
TXSTexas Capital Texas Equity Index ETF<0.000001%23/12/2024
TXSSTexas Capital Texas Sm Cp Eq Idx ETF<0.000001%23/06/2025
ULTYYieldMax Ultra Option Income Strat ETF<0.000001%31/10/2024
URTYProShares UltraPro Russell2000<0.000001%30/06/2025
USVMVictory Shares US Sm Md Cp Val Momt ETF<0.000001%01/09/2022
USVMVictoryShares US Sm Md Cp Val Momt ETF<0.000001%01/09/2022
USVMVictoryShares US Sm Mid Cap Val Mntm ETF<0.000001%01/09/2022
USVMVictoryShares USAA MSCI USA Sm Cp VM ETF<0.000001%01/09/2022
USVMVictoryShares USAA MSCIUSASmCpValMomtETF<0.000001%01/09/2022
UWMProShares Ultra Russell2000<0.000001%30/06/2025
VFMOVanguard US Momentum Factor ETF<0.000001%31/12/2024
VTVanguard Total World Stock ETF<0.000001%30/09/2024
VTHRVanguard Russell 3000 ETF<0.000001%30/06/2025
VTWGVanguard Russell 2000 Growth ETF<0.000001%30/06/2025
VTWOVanguard Russell 2000 ETF<0.000001%30/06/2025
VTWVVanguard Russell 2000 Value ETF<0.000001%30/06/2021
XPHSPDR® S&P Pharmaceuticals ETF<0.000001%23/12/2024
  1    2    3   4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.